well, to answer your question, we hired them, unfortunately. don't know if they were good when we hired them and had something change, or they just put on a front when we hired them. clearly they locked the data as power play to get paid. obviously an extremely low budget operation. i'm hopeful for a quick resolution to this - and also to the day when fighting and lawsuits aren't the news of the day for us.

emotionally, i'm closing the book on 2021 and looking to 2022. i've voted in support of all of the items on the agenda, and have added some shares over the past week, even though i'm already overweight (way overweight). i can't imagine we're not near a low.

personally, i hope we finish COVID the right way - not the short-cut 50 patient read-out, but waiting for a large enough sample size to nail our results. Even if COVID doesn't end up being massive for us, i want us to nail the data and end it with no doubt that we have efficacy. and of course, i want us to get the BLA filed for HIV. Again, i don't see COVID or HIV as huge money makers, but let's finish them as professionally as possible.

But the next chapter in my mind in looking ahead to 2022 is cancer - as SK had mentioned us becoming an oncology company. I think that's the play - whether it's near term (with a BTD granted) or long-term. it should drive huge value eventually - much higher value than our current market cap, which is why i'm buying.

To the extent something happens in the remaining 2 months of this year - i'll take it.